News | February 18, 2022
Ligand posts strong 2021 performance
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Resolv ER may remedy leading causes of blindness in adults
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
Subscribe To Our Newsletter & Stay Updated
